|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cryptocurrency News Articles
Synthetix (SNX) and Derive Drop $27 Million Acquisition Plans After Community Backlash
May 26, 2025 at 11:13 pm
A proposed $27 million acquisition between decentralized derivatives projects Synthetix and Derive has been shelved, following mounting criticism

A proposed $27 million acquisition between decentralized derivatives projects Synthetix and Derive has been shelved, following mounting criticism from token holders and community members on both sides.
The two teams floated a plan in mid-May that would have seen Synthetix absorb Derive — formerly known as Lyra — in a token swap deal that consolidates their technologies and treasuries. The move was set to bring Derive’s decentralized options platform into Synthetix’s ecosystem on Ethereum mainnet, with Synthetix minting 29.3 million new SNX tokens to fund the buyout.
The proposal was formalized through governance channels — SIP-415 and DIP — but both were withdrawn this week.
“The SIP-415 and DIP proposals to merge Synthetix and Derive have been mutually withdrawn after thoughtful discussion and community feedback,” Derive’s team wrote in an update.
Under the deal, Derive would have been valued at $27 million, based on a 27:1 token swap ratio of DRV for SNX. But that valuation quickly drew fire from Derive’s community, especially as the protocol had recently been generating more revenue than Synthetix. Some critics argued that the terms undervalued Derive’s growth and momentum relative to Synthetix’s current market cap.
Synthetix hoped to integrate Derive’s infrastructure into its upcoming Perps V4 launch, which centers on a centralized limit order book built on Ethereum. With the deal off, Synthetix will have to seek other ways to bolster its derivatives offering.
Synthetix strategy lead Ben Celermajer said the three-month token lock-up and the pricing of the deal were among the main sticking points. The team tried to ease concerns by waving the lock-up for smaller DRV holders, but it wasn’t enough.
Synthetix says it’s still committed to building a decentralized derivatives stack on Ethereum, but for now, Derive won’t be part of it.
Opposition from Derive’s community was vocal and detailed. On Derive’s forum, users questioned the fairness of the 27:1 token exchange, with one contributor calling it the equivalent of “selling the bottom.”
Disclaimer:info@kdj.com
The information provided is not trading advice. kdj.com does not assume any responsibility for any investments made based on the information provided in this article. Cryptocurrencies are highly volatile and it is highly recommended that you invest with caution after thorough research!
If you believe that the content used on this website infringes your copyright, please contact us immediately (info@kdj.com) and we will delete it promptly.
-
- Datavecta Forges Global Community Ecosystem to Power International Growth Through Advanced SEO Strategy
- Sep 30, 2026 at 07:55 pm
- Datavecta is building a global community ecosystem to enhance international growth, leveraging advanced SEO strategies and technology-driven services for a connected intelligent trading future.
-
- Illinois Rolls Out Draft Rules for 0.2% Crypto Transaction Tax, Set for 2027
- Sep 30, 2026 at 12:05 pm
- Illinois unveils draft regulations for its upcoming 0.2% digital asset transaction tax, impacting exchanges, transfers, and custody services starting January 1, 2027. The tax applies to the gross value of transactions, not investment gains.
-
-
- Apeing Leads the Charge: Unveiling the Next 100x Crypto Watchlist and 6 Coins to Eye
- Sep 30, 2026 at 12:03 pm
- Amidst a dynamic crypto market, Apeing's presale momentum, coupled with established players like Solana and TRON, is redefining the 100x crypto narrative, offering both early-stage opportunities and proven network strength.
-
-
- OpenAI Unveils GPT-6.1 Sol and Ultrafast Tier, While AstraZeneca Invests Big in Summit Therapeutics
- Sep 30, 2026 at 08:05 am
- OpenAI rolls out GPT-6.1 Sol, offering near-Astra performance at a fraction of the cost, alongside a new 'Ultrafast' speed tier. Meanwhile, AstraZeneca makes a significant $2 billion investment in oncology firm Summit Therapeutics.
-
-
-
- Robinhood Chain Sees Surge in Perps as Spot Trading Cools Amidst Broader Market Shifts
- Sep 29, 2026 at 12:05 pm
- Robinhood Chain's trading landscape is bifurcating: perpetual futures volume is skyrocketing, while spot trading is cooling. This trend hints at a strategic shift in trader behavior on the platform.

































